scholarly journals Mobile software in the follow-up of early breast cancer A randomized study

2021 ◽  
Author(s):  
Johanna Mattson ◽  
Maria Peltola ◽  
Paula Poikonen-Saksela ◽  
Terhi Hermanson ◽  
Jenny Their ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Patient Preference ◽  
Randomized Study ◽  
University Hospital ◽  
Final Visit ◽  
First Year ◽  
Phone Calls ◽  
Mobile Software

Abstract Purpose After primary treatment, patients with early breast cancer are followed-up for 5-10 years. At the Helsinki University Hospital (HUS) five year surveillance consists of three appointments and a phone service operated by a breast cancer nurse practitioner for patients who need counselling about symptoms related to side-effects or potential recurrence. In 2015 HUS launched a mobile software for cancer patients. This study was designed to find out patient preference for the modality of surveillance during the first years as the primary endpoint. Methods 765 patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference. Results 446 patients (60%) contacted breast cancer nurse with either method at least once during the first year. Patient preference was analyzed among the 142 patients who contacted breast cancer nurse with both modalities. Of the patients 40% preferred phone calls, 30% mobile software while 30% considered both modalities equally good. There was no difference in quality of life, symptoms or patient satisfaction between the modalities. Conclusions Of the patients 30% preferred and 60% were willing to use digital solutions as the primary follow-up method for early breast cancer during the first year. There is a need to develop digital services for the follow-up of breast cancer.

Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer

2002 ◽  
Vol 347 (16) ◽  
pp. 1227-1232 ◽  
Author(s):  
Umberto Veronesi ◽  
Natale Cascinelli ◽  
Luigi Mariani ◽  
Marco Greco ◽  
Roberto Saccozzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Randomized Study ◽  
Radical Mastectomy ◽  
Breast Conserving Surgery

scholarly journals Letrozole and anastrozole in early breast cancer postmenopausal patients in oncology department at Suez Canal University Hospital

2019 ◽  
Vol 9 (1) ◽  
pp. 12
Author(s):  
Manar Montasser ◽  
Ihab M.A. Hassanin ◽  
Soheir E. Abdelmohsen ◽  
Maha L. Zamzam
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Postmenopausal Breast Cancer ◽  
University Hospital ◽  
Obese Patients ◽  
Hormone Receptor Positive ◽  
Hormonal Receptor ◽  
Positive Breast Cancer

Background: There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients.Aim of study: To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.Methods: A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points.Results: Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5th year), and 80% OS benefit at 6th year. Overweight patients had better (90% PFS at 5th year) than obese patients (60% PFS at 5th year).Conclusion: Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2nd line after tamoxifen is superior to anastrozole 2nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer.

Follow-up of early breast cancer (BC) patients by telephone or mobile software.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18883-e18883
Author(s):  
Johanna Mattson ◽  
Maria Peltola ◽  
Paula Poikonen-Saksela ◽  
Jenny Their ◽  
Terhi Hermanson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Mobile Software

scholarly journals Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario

2021 ◽  
Vol 28 (3) ◽  
pp. 2190-2198
Author(s):  
Dalia Kamel ◽  
Veronica Youssef ◽  
Wilma M. Hopman ◽  
Mihaela Mates
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Receptor Status ◽  
Cancer Centre ◽  
Radiological Staging

Background: In 2012, the American Society for Clinical Oncology (ASCO) identified five key opportunities in oncology to improve patient care, recommending against imaging tests for the staging of patients with early breast cancer (EBC) at low risk for metastases. Similarly, the European Society of Medical Oncology (ESMO) guideline does not support radiological staging in asymptomatic EBC (aEBC). The purpose of this study was to assess local practice and outcomes of staging investigations (SIs) in aEBC at the Cancer Centre of Southeastern Ontario (CCSEO). Methods: A retrospective electronic and paper chart review was undertaken to identify all aEBC patients treated at our institution between January 2012 and December 2014. Patients with pathological staging of T1-T2 and N0-1 with any receptor status were included. We collected patient demographics, treatment and pathologic tumor characteristics. The use and outcomes of initial and follow-up SIs were recorded. Data were analyzed to determine associations between the use of SIs and clinical characteristics (chi-square tests, independent samples t-tests and Mann–Whitney U tests). Results: From 2012 to 2014, 295 asymptomatic EBC patients were identified. The mean age was 64, 81% were postmenopausal and 76% had breast conserving surgery. Stage distribution was as follows: stage I 42%, stage IIA 37% and stage IIB 21%. Receptor status was as follows: ER+ 84%, HER2+ 13% and triple negative 12%. Adjuvant chemotherapy was received by 36%, Trastuzumab by 10% and endocrine therapy by 76% of patients. Baseline SIs were performed in 168 patients (57%) for a total of 332 tests. Overt metastatic disease was found in five patients (one bone scan and four CT scans). Seventy-one out of the 168 patients (42%) who received initial staging imaging underwent 138 follow-up imaging tests, none of which were diagnostic for metastases. Nine patients with suspicious CT findings underwent biopsies, of which four were malignant (one metastatic breast cancer and three new primaries). Factors significantly associated with SI were as follows: younger age (p = 0.001), premenopausal status (p = 0.01), T2 stage (p < 0.001), N1 stage (p < 0.001), HER2 positive (p < 0.001), triple negative status (p = 0.007) and use of adjuvant chemotherapy (p < 0.001). Conclusions: Over a 3-year period at our institution, more than 50% of aEBC patients underwent a total of 470 initial and follow-up staging tests, yielding a cancer diagnosis (metastatic breast cancer or second primary cancer) in four patients. We, therefore, conclude that routine-staging investigations in aEBC patients have low diagnostic value, supporting current guidelines that recommend against the routine use of SI in this population.

Sign in / Sign up

Export Citation Format

Share Document